NO ONE SHOULD GET HEP‑B

Your role is critical in helping protect adult patients against the serious consequences of hepatitis B

4 out of 5 adults* likely don't have vaccine-induced immunity1,2

*Born before 1991.

3 steps to protect them:

1
IDENTIFY

all eligible adults1†

2
RECOMMEND

vaccination today

3
PROTECT

them from hepatitis B

‍

1: IDENTIFY

‍

Routine identification and recommendation can lead to protection3

In consumer research of 1000 adult patients4‡

66%
of unvaccinated hepatitis B consumers state they have never been evaluated for hepatitis B
9 out of 10
patients are aware of the hepatitis B vaccine and believe it is important

‡In a US consumer study of 1000 participants, inclusion was based on screening criteria of having been vaccinated with any vaccine since age 25, 2+ pharmacy visits in past year, doctor visit frequency, and a balance of gender and ethnicity. Respondents were provided a 30-minute quantitative online survey. Study limitations: screening criteria was used to recruit a subset of participants, so caution should be applied when projecting the results to the US population at large; use of consumer panel may not reflect the demographic and psychographic composition of the total US population.4

‍

2: RECOMMEND

‍

A strong provider recommendation can lead to patient vaccine acceptance5,6

A patient is
4-5 TIMES
more likely to get vaccinated when a strong recommendation is given by an HCP§

What a strong recommendation could sound like:

“Based on your age, you were likely not vaccinated for hepatitis B as a child. Hepatitis B can lead to serious health issues, including liver cancer.|| It is now recommended that all eligible adults get vaccinated. I strongly recommend you get vaccinated today.”

Per the CDC: If your patient lacks documentation of hepatitis B vaccination history, vaccine can be administered.1

HEPLISAV‑B does not treat liver disease, such as cirrhosis and liver cancer3

||For most people, HBV clears on its own. But for those who don’t clear the virus, it can progress to chronic hepatitis B and potentially life-threatening consequences such as liver cancer. From 2018–2022, there were an estimated 13,000–22,000 cases of acute hepatitis B annually in the US.7-9

‍
‍

3: PROTECT

‍

HEPLISAV‑B is the

FIRST AND ONLY 2‑DOSE

adult hepatitis B vaccine that can be completed in just

1 MONTH3,10

Help protect your patients today

†The ACIP recommends hepatitis B vaccination for all adults aged 19–59 and for adults aged ≥60 years with risk factors. Adults aged ≥60 years without known risk factors may receive hepatitis B vaccination. This recommendation does not apply to adults who have received a complete HBV vaccine series in their lifetime or have a history of HBV infection1

§Data from the 2016 National Internet Flu Survey (4305 participants) were analyzed to assess provider vaccination recommendations and early influenza vaccination during the 2016–2017 season among adults aged ≥18 years. Research was analyzed by the CDC to assess strong provider vaccination recommendations based on pediatric patients.5,6

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention

Dosing Efficiency
‍
Resources
‍

This site uses cookies to improve your experience. By continuing to use this website you are agreeing to our Cookie Policy.

INDICATION AND IMPORTANT SAFETY INFORMATION + –

INDICATION
HEPLISAV‑B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV‑B to individuals with a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV‑B, including yeast.

IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV‑B to individuals with a history of severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV‑B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV‑B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV‑B.

Hepatitis B has a long incubation period. HEPLISAV‑B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%‑39%), fatigue (11%‑17%), and headache (8%‑17%).

There are no adequate and well-controlled studies of HEPLISAV‑B in pregnant individuals. Available data, primarily in individuals who received one dose of HEPLISAV‑B in the 28 days prior to or during pregnancy, do not suggest an increased risk of major birth defects and miscarriage.

It is not known whether HEPLISAV‑B is excreted in human milk. Data are not available to assess the effects of HEPLISAV‑B on the breastfed infant or on milk production/excretion.

Vaccination with HEPLISAV‑B may not result in protection of all vaccine recipients.

ADDITIONAL IMPORTANT INFORMATION
HEPLISAV‑B does not treat liver diseases such as cirrhosis or liver cancer.3

Not all liver cancer is caused by the hepatitis B virus.11

Please see full Prescribing Information.

REFERENCES:

1. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. doi:10.15585/mmwr.mm7113a1 2. He WQ, Guo GN, Li C. The impact of hepatitis B vaccination in the United States, 1999–2018. Hepatology. 2022;75(6):1566–1578. doi:10.1002/hep.32265 3. HEPLISAV‑B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2024. 4. Data on file. Dynavax Technologies Corporation. Heplisav‑B consumer quant buying process market research. September 15, 2023. 5. Wolicki J, Miller E. Vaccine administration. Centers for Disease Control and Prevention. Updated August 18, 2021. Accessed May 9, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-6-vaccine-administration.html 6. Lu PJ, Srivastav A, Amaya A, et al. Association of provider recommendation and offer and influenza vaccination among adults aged ≥18 years – United States. Vaccine. 2018;36(6):890-898. doi: 10.1016/j.vaccine.2017.12.016 7. Centers for Disease Control and Prevention. Clinical overview of hepatitis B. Last reviewed February 9, 2024. Accessed June 4, 2024. https://www.cdc.gov/hepatitis-b/hcp/clinical-overview/ 8. Centers for Disease Control and Prevention. Number of reported cases and estimated infections of acute hepatitis B—United States, 2015—2022. Updated June 7, 2024. Accessed January 23, 2025. https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-b/figure-2-1.html 9. Centers for Disease Control and Prevention. Hepatitis B Surveillance 2022. Updated April 4, 2024. Accessed January 28, 2025. https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-b/index.html 10. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older. Updated November 21, 2024. Accessed January 23, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdf 11. National Cancer Institute. Liver cancer causes, risk factors, and prevention. Last updated May 15, 2024. Accessed July 15, 2024. https://www.cancer.gov/types/liver/what-is-liver-cancer/causes-risk-factors